BRIEF-Aetna adds Sarepta's DMD drug Exondys 51 to its coverage effective Novemeber 1,2016

* Aetna adds Sarepta's DMD drug Exondys 51 to its coverage effective Novemeber 1,2016 Source (http://aet.na/2eR7liT)

27 Oct 2016

Fitch Rates Merck's Euro Notes Offering 'A'

(The following statement was released by the rating agency) CHICAGO, October 27 (Fitch) Fitch Ratings has assigned an 'A' rating to Merck & Co., Inc.'s (MRK/Merck) euro notes offering. A complete list of ratings follows at the end of this press release. KEY RATING DRIVERS The company's 'A' rating reflects the following: --Recently introduced therapies, an advancing pipeline and manageable patent expiries should support intermediate- to long-term growth. --Fitch believes that Merck will pursu

27 Oct 2016

UPDATE 3-Bristol hikes 2016 profit forecast as top drugs deliver, shares jump

Oct 27 Bristol-Myers Squibb Co, whose high-profile Opdivo immunotherapy failed an important lung-cancer trial last summer, sharply raised its 2016 profit forecast after strong quarterly sales of other leading medicines.

27 Oct 2016

BRIEF-Intrasense H1 net loss shrinks to 1.1 mln euros

* Reports H1 revenue of 1.5 million euros ($1.6 million) versus 1.3 million euros a year ago

27 Oct 2016

BRIEF-Genticel cash & cash equivalents in line with company's expectations

* Cash & cash equivalents and liquid investments of 12.3 million euros ($13.4 million) as at Sept. 30, 2016, in line with company's expectations Source text: http://bit.ly/2eVNVHR Further company coverage: ($1 = 0.9181 euros) (Gdynia Newsroom)

27 Oct 2016
BSE OIL & GAS -0.72%
BSE AUTO -1.36%
BSE POWER -0.45%
BSE-CG -0.56%


  • Sectors
  • Asia
  • U.S.
  • Europe

Sector Summary


Tata group accuses ousted chairman Cyrus Mistry of malice

NEW DELHI/MUMBAI Tata Sons accused its former chairman, Cyrus Mistry, of making "unsubstantiated claims and malicious allegations" against the Indian conglomerate as the gloves came off in a bitter and highly public row over his sacking earlier this week. | Video